Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Kristian Villumsen

Market Cap

25.46 Billion USD

Sector

Healthcare

Website

https://www.coloplast.com

Description

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.

Read More

Overview

Value

9

Growth

32

Health

44

Management

21

Analyst Opinion

91

Total

39

All Scores Out Of 100

Best Features

  • Liked by analysts
  • Has strong dividend growth
  • 0

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • There is a history of diluting shareholders
  • Has a high level of debt
  • Does not hold enough liquid assets to cover short term liabilities
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • Price-to-earnings ratio of 52.3 is higher than the market average (19.6x)
  • High preportion of income is paid as dividend

Market Peers

CLPBY

Key Figures

PE Ratio (TTM)

52.34

Margin Of Safety (DCF)

-43.36%

Revenue Growth (5 Year Average)

4.76%

Ratings Consensus

Strong Buy

Share Buybacks

-0.07%

Dividend Yeild (TTM)

2.22%

Valuation

Value Score

9

  • Estimated intrinsic-value of 6.96 USD is lower than current price ( 11.99 USD)
  • Price-to-earnings ratio of 52.3 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 1.23% is worse than the market average (4.7%)
  • Margin-of-safety of -43.36% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 56.6 USD

Current Price: 12.3 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

52.34x

Free Cashflow Yeild

1.23%

PE/Earnings Growth

N/A

Price/Book

0.75x

Growth

Growth Score

32

  • Revenue growth has improved this yeara
  • 5 Year Average Revenue growth of 4.76% is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of 8.16% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 0.79% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

4.76%

Earnings Growth

8.16%

Cashflow Growth

0.79%

Health

Health Score

44

  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Has a high level of debt
  • Debt repayments significantly impact cashflow

Altman Z Score

2.03

Piostroski Score

7.00

Debt/Equity

2.26x

Current Assets/Liabilities

N/Ax

Free Cashflow/Total Debt

N/Ax

Debt/Capital

N/Ax

Management

Management Score

21

  • Has issued new shares to finance growth when share price is high
  • Has returned higher dividends when earnings have risen
  • Return-on-capital-employed of N/A is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of N/A is lower than the market average (15%)

Average Buybacks/Dilution

-0.07%

Recent Buybacks/Dilution

-0.23%

5 Year Price Volitility

21.82%

Return On Assets

N/A

Return On Capital Employed

N/A

Return On Equity

N/A

Return On Free Cashflow

N/A

Return On Investments

N/A

Analysts

Analyst Opinion

91

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Coloplast A/S

Currency

USD

Beta

0.221568

Vol Avg

84416

Ceo

Mr. Kristian Villumsen

Cik

0001294325

Cusip

Exchange

Other OTC

Full Time Employees

14572

Industry

Medical Instruments & Supplies

Sector

Healthcare

Ipo Date

2014-01-13

Address

Holtedam 1-3

City

Humlebæk

State

Country

DK

Zip

3050

Phone

45 49 11 11 11

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies